Alnylam Pharmaceuticals stock falls on silencer drug concerns
What it means
- What to watch: Pricing pressure and trial misses are the two big risks in healthcare, and the first one hits the whole aisle.
- How the stock is trading: $ALNY -17.99% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$ALNY last changed hands at $190.59, -17.99% on the session, 60% below its 52-week high of $479.79 and 6.0% above its low of $179.87 — within a tenth of its 52-week low. Over the year it has ranged 167% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ALNY page.
How much coverage it is getting
In the last 30 days Wook has filed 2 stories about $ALNY — 2 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal — something has the newsroom's attention. Across those stories 0 read bullish, 2 neutral and 0 bearish. This one reads bearish, so it sits in a small minority of the run. This is the only one from Investing.com; the rest came from other outlets. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$ALNY earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $ALNY page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ALNY is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. It reads bearish at medium severity because of “fall” and “concern” in the wording, with nothing on the bullish side to offset them. It was matched to $ALNY. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 28, 2026. $ALNY has moved -19.62% ($237.10 to $190.59). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.